Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
about
DNMT3A Mutations in Acute Myeloid LeukemiaIDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid LeukemiaEfficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemiaPrognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.Metabolism and the leukemic stem cell.Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results.IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expressionMutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patientsMutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adultsDiagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.Cancer-associated isocitrate dehydrogenase mutationsMolecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patientsTP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary MyelofibrosisPrognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysisPotential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLClonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia.Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemiaHuman BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia.Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotypeDynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome.Isocitrate dehydrogenase mutations in myeloid malignancies.
P2860
Q27559610-75187834-AB57-4DDB-899E-68287DE85A73Q27851565-B59DB6D1-8D29-4BD0-A231-8A97132D0551Q27851805-F2249014-CC4C-4CD4-A8C5-83BABFB4A32CQ27852437-D661FAE2-E2C4-4B74-8B6F-0AD9591F3FA4Q33431399-1EB69713-F88B-441C-B500-1D17A2974C4CQ33702409-FA992989-BF5A-467D-84E1-39C277552694Q33746724-74303A3E-3965-4E11-BFDF-DCBE04DDC8BEQ33769072-3CCFE425-AE83-44FB-852B-2C1AC4124A98Q33782633-DE9B60FF-122C-4E69-B556-72BA1B308D6DQ33795007-3C1039D4-F700-4F0D-A953-73FA0776B856Q34053028-AE6D2582-4ED1-4FAA-A2E3-25F960AAECBBQ34109454-43AEA633-280E-43DC-BDF9-B2B836AF195DQ34562170-D87D36BB-1AF1-4F2E-9828-9D8A67BB01C7Q34647741-88C3AE9B-97FC-455B-9310-330D36C17D35Q34649120-DA4C4F11-05F9-4625-B4F7-8A2C60D2C32FQ34651312-B18D5489-5689-4DA8-91FB-FAF725247DCAQ34755642-090B9C97-A9BF-47DD-810F-919D6315317AQ34764504-4332049D-D279-4A66-B7D9-F62BA0AE99CDQ35030952-CDFAB658-F0AB-412C-9727-0E03B36D8C26Q35078037-C8CF7B0A-DBC8-4DE5-8D1A-C58335099382Q35346433-A7758939-C43D-4968-B387-E2DB13496E2FQ35441165-87AB592C-2595-4E17-8CF6-860258DF2757Q35524250-279C78FD-64EA-4E0F-B6E6-909E6BC132EFQ35568696-61782867-2495-4124-A760-24DEB4743245Q35586677-847238BB-1F20-4627-A220-3B30DF96E097Q35705274-1FF27D3B-A7BD-4E1E-9309-4A19EFB8EE58Q35873466-2E47EF4B-C319-4924-8C5D-A1F2DC5CA28CQ35921904-82DE61DC-9DEC-4928-B93E-C8108F551E37Q36001930-5A0B3D04-1B3A-4CDF-AAC0-971BE883840FQ36322776-3C1890AA-4B98-4BDB-A803-2DF365CF34D0Q36364763-FE694C57-4EF7-4262-B4FB-36525393DC8DQ36439908-E3C5D83D-A376-42E9-B662-3D2053F74130Q36797201-AE1EF53D-6132-48B4-9F39-CABF0358A576Q36842838-71664007-FC28-4FBD-A7A6-F365D711B1C9Q36928342-742AD3CC-C0DD-4C1F-829E-287302EAB038Q36962514-663B4E2C-A56F-4648-A3C5-4DA1EC05875FQ37351908-53ADE36A-EEF1-4B21-8C85-692E5E863E7FQ37432049-A44F2020-6262-4CF0-8DA7-9B12B1AC1666Q37555315-92971631-C837-4994-9527-7ADE33385853Q37625630-6A2AB5F7-AD64-4106-8600-CBB9E080D2B5
P2860
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Distinct clinical and biologic ...... rate dehydrogenase 1 mutation.
@en
Distinct clinical and biologic ...... rate dehydrogenase 1 mutation.
@nl
type
label
Distinct clinical and biologic ...... rate dehydrogenase 1 mutation.
@en
Distinct clinical and biologic ...... rate dehydrogenase 1 mutation.
@nl
prefLabel
Distinct clinical and biologic ...... rate dehydrogenase 1 mutation.
@en
Distinct clinical and biologic ...... rate dehydrogenase 1 mutation.
@nl
P2093
P50
P1433
P1476
Distinct clinical and biologic ...... trate dehydrogenase 1 mutation
@en
P2093
Bor-Shen Ko
Chi-Fei Huang
Chia-Wen Liu
Chien-Yuan Chen
Fen-Yu Lee
Mei-Hsuan Tseng
Ming-Chi Liu
Shang-Ju Wu
Shang-Yi Huang
Szu-Chun Hsu
P304
P356
10.1182/BLOOD-2009-11-253070
P407
P577
2010-01-22T00:00:00Z